4,901 trials
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin — 3627.171; 4076.521; 6981.833; 6564.938…
Non Hodgkin Lymphoma · Follicular Lymphoma · Relapsed Follicular Lymphoma
Primary: Safety and Tolerability: Frequency and Severity of Adverse Events (CTCAE v4.03) — 0; 0; 3; 3 Participants
HIV Infections
Primary: Number of Participants With Grade 2 and Higher Adverse Events (AEs) — 1; 1; 20; 18 Participants
Recurrent Malignant Solid Neoplasm · Recurrent Melanoma · Recurrent Primary Central Nervous System Neoplasm
Primary: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose of Cabozantinib S-malate — 40 mg/m^2
Childhood Solid Neoplasm · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: Maximum Tolerated Dose (MTD) of Prexasertib — 150 mg/m^2
Malaria
Primary: Area Under the Concentration-time Curve From Hour 0 to the Last Sampling Point (AUC 0-t) for Pyronaridine and Dihydroartemisinin (DHA) — 11640; 11324; 1119; 829 ng*h/ml
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CAP256V2LS Product Administration — 5; 4; 0; 1 Participants
Malignant Central Nervous System Neoplasm · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Number of Participants With Grade 2 or Higher Toxicities — 0; 0 Participants
Healthy Volunteers
Primary: Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) — 471.9; 603.1…
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 1; 0; 0 Participants
Surgical Skin Preparation
Primary: Number of Subjects With Plasma Levels of Chlorexidine Following Systemic Exposure After a Single Topical Application of CHG. — 0; 0; 0 Participants
Alcohol Use Disorder
Primary: Percent Drinking Days — 38.5; 46.6; 53 percentage of drinking days — p=0.009
Healthy · Male
Primary: Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib — 2700; 1530 h*ng/mL
Malaria
Primary: Arm A Pharmacokinetic Parameters of Metoprolol & α-hydroxymetoprolol: Area Under Curve (AUC)0-t, AUC0-∞ — 685; 746; 895; 958 ng.h/ml
Cachexia · Non-Small-Cell Lung Cancer · Pancreatic Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 10; 4 Participants